A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine

Vaccine

Volumn 26, Issue 15, 2008, Pages 1893-1901

  Wang, Xueju ^a   Bao, Musheng ^a   Wan, Min ^a   Wei, Hongfei ^a   Wang, Li ^a   Yu, Hongtao ^b   Zhang, Xuesong ^c   Yu, Yongli ^a   Wang, Liying ^a  

^a JILIN UNIVERSITY   (China)

^b Changchun Institute of Biological Products   (China)

^c Blood Center of Jilin Province   (China)

Author keywords

Adjuvant; CpG ODN; Rabies vaccine

Indexed keywords

ALUMINUM; BW006; CPG OLIGODEOXYNUCLEOTIDE; RABIES VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; FEMALE; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLIGODEOXYRIBONUCLEOTIDES; RABIES; RABIES VACCINES; RABIES VIRUS; SURVIVAL ANALYSIS;

EID: 40849095781     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.01.043     Document Type: Article

References (43)

1. WHO Expert Consultation on Rabies. First report. World Health Organization, Geneva, 1992 (WHO Technical Report Series; 931).
2. Hemachudha T., Sunsaneewitayakul B., Mitrabhakdi E., Suankratay C., Laothamathas J., Wacharapluesadee S., et al. Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies. Int J Infect Dis 7 1 (2003) 76-77
3. Barrett B. Rabies heads fatal disease list again. Vet Newslett 4 3 (2006) 7
4. Tang X.C., Luo M., Zhang S.Y., Fooks A.R., Hu R.L., and Tu C.C. Pivotal role of dogs in rabies transmission, China. Emerg Infect Dis 11 12 (2005) 1970-1972
5. Centers for Disease Control and Prevention: Human rabies prevention-United States, 1999: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-1):p. 1-17.
6. Shayam C., Duggal A.K., Kamble U., and Agarwal A.K. Post-exposure prophylaxis for rabies. JIACM 7 1 (2006) 39-46
7. Cabasso V.J., Dobkin M.B., Roby R.E., and Hammar A.H. Antibody response to a human diploid cell rabies vaccine. Appl Microbiol 27 3 (1974) 553-561
8. Berlin B.S., and Goswick C. Rapidity of booster response to rabies vaccine produced in cell culture. J Infect Dis 50 5 (1984) 785
9. Berlin B.S. Rabies vaccine adsorbed: neutralizing antibody titers after three-dose pre-exposure vaccination. Am J Public Health 80 4 (1990) 476-478
10. Lin H.X., and Perrin P. Influence of aluminum adjuvant to experimental rabies vaccine. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 13 2 (1999) 133-135
11. Stacey K.J., and Blackwell J.M. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67 8 (1999) 3719-3726
12. Malanchère-Brès E., Payette P.J., Mancini M., Tiollais P., Davis H.L., and Michel M.L. CpG oligodeoxynucleotides with hepatitis B surface antigen for vaccination in HBsAg-transgenic mice. J Virol 75 14 (2001) 6482-6491
13. Ivory C.P., Keller K., and Chadee K. CpG-Oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica Gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils. Infect Immun 74 1 (2006) 528-536
14. Klinman D.M., Xie H., and Ivins B.E. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci 1082 1 (2006) 137-150
15. Alignani D., Maletto B., Liscovsky M., Rópolo A., Morón G., and Pistoresi-Palencia M.C. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol 77 6 (2005) 898-905
16. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22 (2004) 3136-3143
17. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186 10 (1997) 1623-1631
18. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
19. Yi A.K., Chang M., Peckham D.W., Krieg A.M., and Ashman R.F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol 160 (1998) 5898-5906
20. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160 2 (1998) 870-876
21. Liu N., Ohnishi N., Ni L., Akira S., and Bacon K.B. CpG directly induces T bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 4 7 (2003) 687-693
22. He B., Qiao X., and Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173 7 (2004) 4479-4491
23. Hartmann G., Weiner G.J., and Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96 16 (1999) 9305-9310
24. Gursel M., Verthelyi D., and Klinman D.M. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 32 9 (2002) 2617-2622
25. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24 6 (2004) 693-701
26. Klinman D.M. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine. Expert Rev Vaccines 5 3 (2006) 365-369
27. Mannon R.B., Nataraj C., and Pisetsky D.S. Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides. Cell immunol 201 1 (2000) 14-21
28. Simani S., Nejad P.M., Amirkhani A., Feizabadi M.M., Elahi E., and Fayaz A. Comparison of three serological tests for titration of rabies antibodies in immunized individuals. Arch Iran Med 2 3 (1999) 125-127
29. Rooijakkers E., Groen J., Uittenbogarrd J., van Herwijnen J., and Osterhaus A. Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Dev Biol Stand 86 (1996) 137-145
30. Reed L.J., and Muench H. A simple method of estimating fifity percent end-points. Am J Hyg 27 3 (1938) 493-497
31. Krieg A.M. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc 4 3 (2007) 289-294
32. Klaus G.G., Pepys M.B., Kitajima K., and Askonas B.A. Activation of mouse complement by different classes of mouse antibody. Immunology 38 4 (1979) 687-695
33. Nimmerjahn F., and Ravetch J.V. Fcγ receptors: old friends and new family members. Immunity 24 1 (2006) 19-28
34. Kipps T.J., Parham P., Punt J., and Herzenberg L.A. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 161 1 (1985) 1-17
35. Jegerlehner A., Maurer P., Bessa J., Hinton H.J., Kopf M., and Bachmann M.F. TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178 4 (2007) 2415-2420
36. Markine-Goriaynoff D., van der Logt J.T., Truyens C., Nguyen T.D., Heessen F.W., Bigaignon G., et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 12 2 (2000) 223-230
37. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5 6 (2006) 471-484
38. Furukawa Y., Bangham C.R.M., Taylor G.P., Weber J.N., and Osame M. Frequent reversible membrane damage in peripheral blood B cells in human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Clin Exp Immunol 120 2 (2000) 307-316
39. VandenDriessche T., Thorrez L., Naldini L., Follenzi A., Moons L., Berneman Z., et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 100 3 (2002) 813-822
40. Infante-Duarte C., and Kamradt T. Thl/Th2 balance in infection. Springer Semin Immunopathol 21 3 (1999) 317-338
41. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Röcken M., Wagner H., et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 160 8 (1998) 3627-3630
42. Wunderli P.S., Dreesen D.W., Miller T.J., and Baer G.M. Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice. Am J Vet Res 64 4 (2003) 491-498
43. WHO. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines. WHO Tech Rep Ser No. 840 (Annex 5) 1994.